Verdence Capital Advisors LLC Takes Position in IQVIA Holdings Inc. $IQV

Verdence Capital Advisors LLC acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 22,922 shares of the medical research company’s stock, valued at approximately $3,612,000.

A number of other large investors have also recently made changes to their positions in the stock. Concord Wealth Partners grew its holdings in shares of IQVIA by 60.1% during the second quarter. Concord Wealth Partners now owns 373 shares of the medical research company’s stock valued at $59,000 after buying an additional 140 shares during the last quarter. MGO One Seven LLC grew its holdings in shares of IQVIA by 14.9% during the second quarter. MGO One Seven LLC now owns 3,412 shares of the medical research company’s stock valued at $538,000 after buying an additional 443 shares during the last quarter. LRI Investments LLC grew its holdings in shares of IQVIA by 1.5% during the second quarter. LRI Investments LLC now owns 24,071 shares of the medical research company’s stock valued at $3,793,000 after buying an additional 361 shares during the last quarter. CWM LLC lifted its position in IQVIA by 171.7% during the second quarter. CWM LLC now owns 32,705 shares of the medical research company’s stock valued at $5,154,000 after purchasing an additional 20,666 shares during the period. Finally, OFI Invest Asset Management lifted its position in IQVIA by 22.0% during the second quarter. OFI Invest Asset Management now owns 682 shares of the medical research company’s stock valued at $107,000 after purchasing an additional 123 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of the business’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares of the company’s stock, valued at $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Eric Sherbet sold 5,800 shares of the business’s stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares of the company’s stock, valued at $5,165,178.90. This represents a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on IQV. Mizuho boosted their target price on shares of IQVIA from $190.00 to $225.00 and gave the company an “outperform” rating in a research report on Friday, July 25th. Redburn Partners set a $214.00 target price on shares of IQVIA in a research report on Wednesday, September 3rd. Evercore ISI boosted their target price on shares of IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research report on Wednesday. William Blair reiterated an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Finally, Truist Financial upped their price objective on shares of IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a research report on Wednesday, July 23rd. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $236.45.

IQVIA Stock Down 2.3%

IQV stock opened at $198.35 on Monday. The stock has a market capitalization of $33.72 billion, a P/E ratio of 28.70, a P/E/G ratio of 2.18 and a beta of 1.32. The firm has a 50-day simple moving average of $189.02 and a 200-day simple moving average of $168.11. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $237.34.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to analysts’ expectations of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.